| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $83M | ||
| $75M |
Buys | $20,134 | 1 | 100 |
Sells | $0 | 0 | 0 |
| Grant Grady III | director | 1 | $20,134 | 0 | $0 | $20,134 |
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Over the last 12 months, insiders at Aptevo Therapeutics Inc. have bought $20,134 and sold $0 worth of Aptevo Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Aptevo Therapeutics Inc. have bought $20,134 and sold $16.87M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Grant Grady III (director) — $20,134.
The last purchase of 13,513 shares for transaction amount of $20,134 was made by Grant Grady III (director) on 2025‑11‑10.
| Increased Positions | 8 | +50% | 19,652 | +71.58% |
| Decreased Positions | 8 | -50% | 26,808 | -97.64% |
| New Positions | 5 | New | 16,883 | New |
| Sold Out Positions | 5 | Sold Out | 26,661 | Sold Out |
| Total Postitions | 16 | 0% | 20,299 | -26.06% |
| Point72 Asset Management, L.P. | $156.00 | 1.67% | 16,665 | +16,665 | New | 2025-09-30 |
| Drw Securities, Llc | $69.00 | 0.73% | 7,305 | +7,305 | New | 2025-09-30 |
| Virtu Financial Llc | $20.00 | 0.21% | 2,127 | +2,127 | New | 2025-09-30 |
| Focus Partners Wealth | $5.00 | 0.06% | 556 | +556 | New | 2025-09-30 |
| Osaic Holdings, Inc. | $3.00 | 0.04% | 361 | +180 | +99.45% | 2025-09-30 |
| Ubs Group Ag | $3.00 | 0.03% | 315 | +315 | New | 2025-09-30 |
| Tower Research Capital Llc (Trc) | $1.00 | 0.01% | 80 | +14 | +21.21% | 2025-09-30 |
| Sbi Securities Co., Ltd. | $0 | <0.01% | 32 | <1 | -3.03% | 2025-09-30 |
| Citigroup Inc | $0 | 0% | 4 | +4 | New | 2025-09-30 |
| Bank Of America Corp /De/ | $0 | 0% | 2 | +2 | New | 2025-09-30 |